Multi-arm Optimization of Stroke Thrombolysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 514 participants.
Also called NCT03735979
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 514 participants
- Sponsor
- Registry
-
NCT03735979
-
- Other papers using this trial's data
- Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
- Comparison of Local and Centrally Adjudicated Modified Rankin Scale Scores in the MOST Trial
- Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03735979. Randomized; double masking; primary purpose treatment. Start 2019-10-15 (actual); primary completion 2023-12-01 (actual). Results posted on 2024-11-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Multi-arm Optimization of Stroke Thrombolysis
- Acronym
- MOST
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Argatroban
- Intervention (Drug)
- Eptifibatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Washington University School of Medicine
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
Record details
- Record id
cardio:ct-nct03735979- Content hash
78db085fde759b506691c12d091f808b7472dd7d901b9f7e18700bc2f64367f7